Type 1 Diabetes Clinical Trial
Official title:
Randomized Controlled Trial to Evaluate the Effect of 3 Months Use With Interactive Computer Game- "My Diabetic Friend"-Comparing to Conventional Diabetes Education on Metabolic Control, Quality of Life and Diabetes Knowledge in Children With Type 1 Diabetes.
Verified date | May 2014 |
Source | Rabin Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
A randomized controlled study to evaluate the effect of 3 months use with interactive
computer game- "My Diabetic Friend"- comparing to conventional diabetes education on
metabolic control, quality of life and diabetes knowledge.Patients will be randomized into
two groups- one group will be supplied with interactive computer game, "My Diabetic friend",
installed on a computer designed for children's educational needs for a period of three
months and the other group will be supplied with the same computer without the interactive
computer game for three months. Metabolic control, quality of life and diabetes knowledge
will be evaluated before and after the use of the computer.
The trial is consisting of two main periods: 3 months of the main study period and an
optional extension period consisting of the following 3 months :
The study will include two main periods;
1. Period 1 which will last 3 months, in a randomized controlled manner, this period will
serve as the main study period to assess the primary and secondary endpoints of the
study.
2. Period 2: this extension period will not be an integral part of the study, and only
patients who are willing will take part at this period, will continue to participate at
the optional extension period. During the extension period, patients in the
intervention group will be offered to continue the use of the Computer game -"My
diabetic friend) for the following 3 months, and patients who participated at the
control group during period 1, will be offered to start to use the Computer Game - "My
Diabetic Friend" for the following 3 months.
Status | Completed |
Enrollment | 30 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 7 Years to 11 Years |
Eligibility |
Inclusion Criteria: 1. Type 1 diabetes diagnosed at least one year prior to study entry. 2. Age:7-11 years old. 3. Treatment either with CSII or MDI. 4. HbA1c>8.0% 5. Signing an informed consent form. Exclusion Criteria: 1. Any significant disease or conditions, including psychiatric disorders that in the opinion of the investigator are likely to affect subject compliance or subject's ability to complete the study. 2. Inability to understand/ complete the questionnaires. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Israel | Schneider Medical Center | Petach- Tikva |
Lead Sponsor | Collaborator |
---|---|
Rabin Medical Center | Intel Corporation |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of life | Quality of life questionnaires will be completed | After 12 weeks (end of study) | No |
Secondary | Metabolic control | HbA1c will be measured | After 12 weeks (end of study) | No |
Secondary | Diabetes knowledge | Diabetes knowledge questionnaires will be completed | After 12 weeks | No |
Secondary | Patient's gaming duration | The frequency and the duration of use of the interactive computer game by each participant will be monitored by the study team | After 12 weeks | No |
Secondary | Compliance to diabetes treatment | Patient's parents will undergo clinical interview about patient's diabetes adherence | After 12 weeks | No |
Secondary | Average glucose levels | After 12 weeks (end of study) | No | |
Secondary | Average number of blood glucose measurements | After 12 weeks (end of study) | No | |
Secondary | Measurements within normal range | After 12 weeks (end of study) | No | |
Secondary | Hypoglycemia events | After 12 weeks (end of study) | No | |
Secondary | Hyperglycemia events | After 12 weeks (end of study) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |